SOLICITATION NOTICE
B -- Staining of Colorectal Tumor Tissue Microarrays
- Notice Date
- 8/22/2008
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80199-NG
- Archive Date
- 9/17/2008
- Point of Contact
- Ashley L. Virts, , Malinda L Holdcraft,, Phone: (301) 402-4509
- E-Mail Address
-
virtsa@mail.nih.gov, holdcram@exchange.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis, tissue core shipment and protein staining of colorectal tumor tissue micro arrays (TMA’s) constructed in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial with The University of California at Los Angeles; Department of Pathology and Laboratory Medicine; Reed Neurological Research Center, Rm. 3155; 710 Westwood Blvd.; Los Angeles, California, 90095. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 611310 the business size standard is 6.5M employees. The period of performance for this procurement shall be ten (10) months from date of award. This procurement is to validate the automated Aperio ScanScope scoring system in a pilot study by comparing results with those by traditional pathologist manual review of the immunohistochemistry (IHC)-stained TMA slides. Upon satisfactory performance, the full study will be implemented by the automated Aperio ScanScope scoring system to determine protein staining status of COX-2, COX-1, AMACR, and global DNA methylation for 14 colorectal carcinoma TMAs and 5 adenoma TMAs. The PLCO colorectal tumor TMAs for the 500 colon carcinoma cases (on 14 TMAs) and 700 colorectal adenoma cases (on 5 TMAs).provide opportunities to study altered protein expression of the tumors and relate the tumor characteristics with etiologic factors. Utilizing the tumor TMAs established at UCLA, we aim to evaluate (1) the associations of non-steroid anti-inflammatory drugs (NSAIDs) with subtypes of colorectal carcinoma and adenoma, as determined by protein staining status of COX-2, COX-1, and AMACR, and (2) associations of folate intake with subtypes of colorectal carcinoma and adenoma as determined by tumor global methylation status. Previous studies examining risk factors by molecular subtypes of colorectal tumors were mostly small or case-control studies. Confirmation is needed in a large, well-designed study, such as the PLCO Trial, where cases and controls had equal opportunity for detection of colorectal neoplasia and have reported life style and dietary behaviors prior to cancer diagnosis. The specific aims require premalignant adenomas and malignant cancers to distinguish early events from consequences of malignancy, to inform etiology and effective prevention strategies. The contractor shall perform the following tasks. 1. Ship all tubes containing approximately 1200 PLCO colorectal tumor tissue cores and 40 test cores in room temperature to NCI 2. Validate protein staining data of COX-2, COX-1, AMACR, and global methylation status by comparing quantitative scoring to manual pathologist scoring of IHC-stained slides of test array of 20 cases 3. Cut 15 TMA slides for each of the 14 colorectal carcinoma TMAs and 5 adenoma TMAs 4. Obtain protein staining data for COX-2, COX-1, AMACR, and global methylation status on 19 PLCO TMA slides of 1200 colorectal tumor cases (500 carcinoma and 700 adenoma cases) The University of California at Los Angeles (UCLA) has collected PLCO tissue cores, constructed the TMAs, and established the test array of colorectal tumors for the pilot study. UCLA is the repository for PLCO Trial pathology tumor arrays; all the samples and associated TMA data are physically stored at UCLA. No other source known to the NCI has the materials to provided the required services. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 1:00 p.m. ET on September 2, 2008. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Malinda Holdcraft: holdcram@exchange.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-80199-¬NG on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=1e28298257befd50b5ab6282bcf210b2&tab=core&_cview=1)
- Record
- SN01649080-W 20080824/080822223514-1e28298257befd50b5ab6282bcf210b2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |